Susan J Done, MBA, PhD, MB BChir, MB BCh, FRCPC

In our lab the primary focus is the identification and characterization of molecular alterations that lead to the development of solid cancers, particularly breast cancer. It is believed that the study of these changes will lead to the identification of potential diagnostic, prognostic and predictive markers and also therapeutic targets.

Cancer results from a progressive accumulation of genetic alterations. In some organ systems (eg, colon, cervix) it has been demonstrated that these increasing degrees of genetic perturbation are accompanied by increasing degrees of histologic dysplasia. Other tissues are less accessible making the establishment of these links more difficult.

In the breast, certain preneoplastic and preinvasive lesions (hyperplasias and ductal carcinoma in situ) have been linked to invasive breast cancer by the increased relative risk of future invasive disease they confer. However, it has not been clearly established whether these lesions have the potential to progress to invasive breast cancer or are merely markers of increased risk. Advances in tissue microdissection and PCR technologies have made possible the study of molecular alterations in these small, histologically defined lesions.

We believe it is important to localize particular genetic aberrations to specific cells thereby enabling a correlation between histologic and genetic changes. This correlation is effected using advanced molecular techniques in several ways: firstly, tissue microdissection involving laser capture microdissection can be used in some cases; and secondly, fluorescence in situ hybridization (FISH) analysis can allow detection of gene copy number in specific cells.

Current projects in the lab involve the use of gene microarray chips to identify genes and chromosomal regions that are amplified or deleted in the transition from preinvasive to invasive breast cancer and determination of the extent of genomic instability in histologically normal tissue adjacent to invasive carcinoma.

Related Links

Dis Model Mech. 2019 Jul 26;12(7):
Lourenco C, Kalkat M, Houlahan KE, De Melo J, Longo J, Done SJ, Boutros PC, Penn LZ
J Natl Cancer Inst. 2019 Jun 24;:
Chiarelli AM, Blackmore KM, Muradali D, Done SJ, Majpruz V, Weerasinghe A, Mirea L, Eisen A, Rabeneck L, Warner E
J Natl Cancer Inst. 2019 Jun 24;:
Chiarelli AM, Blackmore KM, Mirea L, Done SJ, Majpruz V, Weerasinghe A, Rabeneck L, Muradali D
J Clin Pathol. 2019 Feb;72(2):120-132
Mrkonjic M, Berman HK, Done SJ, Youngson B, Mulligan AM
Mol Cell. 2018 Oct 30;:
Kalkat M, Resetca D, Lourenco C, Chan PK, Wei Y, Shiah YJ, Vitkin N, Tong Y, Sunnerhagen M, Done SJ, Boutros PC, Raught B, Penn LZ
Cell Rep. 2018 Oct 16;25(3):702-714.e6
An Y, Adams JR, Hollern DP, Zhao A, Chang SG, Gams MS, Chung PED, He X, Jangra R, Shah JS, Yang J, Beck LA, Raghuram N, Kozma KJ, Loch AJ, Wang W, Fan C, Done SJ, Zacksenhaus E, Guidos CJ, Perou CM, Egan SE
J Clin Pathol. 2018 Jul 07;:
Gai L, Done SJ, Cook D, Denic N, Erivwo P, Voisey K, Kao K
Nat Commun. 2017 Nov 01;8(1):1245
Abdalla M, Tran-Thanh D, Moreno J, Iakovlev V, Nair R, Kanwar N, Abdalla M, Lee JPY, Kwan JYY, Cawthorn TR, Warren K, Arneson N, Wang DY, Fox NS, Youngson BJ, Miller NA, Easson AM, McCready D, Leong WL, Boutros PC, Done SJ
Breast. 2017 Aug 03;:
Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Gu S, Fong C, Tuck A, Youngson B, Miller N, Done SJ, Chang MC, Sengupta S, Elavathil L, Jani PA, Bonin M, Lalani N, Paszat L



Associate Professor, Departments of Medical Biophysics and Laboratory Medicine & Pathobiology, University of Toronto